In a phase 1-2 trial in patients with telomere syndromes, danazol lengthened telomeres (11 of 12 evaluable patients at 24 months) with blood count responses, but with liver and muscle toxicity.
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).